Digestive Signs and Symptoms
25 drugs in active Digestive Signs and Symptoms trials · Updated 20 Nov 2026
Furthest along
3 approved
10 in Phase 3
Drugs
25
In active trials, any stage
Trials
30 active
12 sub-diseases included
Drugs25
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Phase 3 | 1 Dec 2026soonPhase 3 trial completes | |||
| Next date | 1 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Nausea and Vomiting, Obesity | ||||
| Open drug page | |||||
Cell therapy |
Phase 3 | Dec 2026Phase 3 trial completes | |||
| How it works | A cell therapy | ||||
| Next date | Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Fecal Incontinence | ||||
| Open drug page | |||||
Dopamine and norepinephrine reuptake inhibitor |
Phase 3 | Dec 2026Phase 3 trial completes | |||
| Next date | Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Binge-Eating Disorder | ||||
| Open drug page | |||||
Monoclonal antibody |
Pfizer · Public PFE |
Phase 2/3 | 23 Jan 2028Phase 2/3 trial completes | ||
| How it works | An antibody | ||||
| Next date | 23 Jan 2028 · Phase 2/3 trial completes | ||||
| Also tested for | Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma and 1 more | ||||
| Open drug page | |||||
— |
Phase 2/3 | Mar 2028Phase 2/3 trial completes | |||
| Next date | Mar 2028 · Phase 2/3 trial completes | ||||
| Also tested for | Choline Deficiency, Liver Injury | ||||
| Open drug page | |||||
Calcitonin gene-related peptide receptor antagonist |
Pfizer · Public PFE |
Phase 3 | 9 Jan 2029Phase 3 trial completes | ||
| Next date | 9 Jan 2029 · Phase 3 trial completes | ||||
| Also tested for | Pediatric Migraine, Acute Treatment of Migraine and 1 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Phase 2/3 | Dec 2029Phase 2/3 trial completes | |||
| How it works | An antibody | ||||
| Next date | Dec 2029 · Phase 2/3 trial completes | ||||
| Also tested for | Cancer-associated Cachexia | ||||
| Open drug page | |||||
Unmodified immunoglobulin |
Phase 2/3 | Mar 2030Phase 2/3 trial completes | |||
| How it works | An antibody | ||||
| Next date | Mar 2030 · Phase 2/3 trial completes | ||||
| Also tested for | Cachexia; Cancer, Cachexia and 5 more | ||||
| Open drug page | |||||
— |
Phase 3 | — | |||
| Also tested for | Dyspepsia | ||||
| Open drug page | |||||
— |
Phase 3 | — | |||
| Also tested for | Parenteral Nutrition | ||||
| Open drug page | |||||
No drugs match “”.
Included12
| Sub-disease | Drugs | Active trialsTrials |
|---|---|---|
| Nausea 1 sub-disease | 6 | 8 |
| Vomiting 2 sub-diseases | 7 | 7 |
| Diarrhea 1 sub-disease | 5 | 5 |
| Anorexia | 3 | 4 |
| Constipation 1 sub-disease | 3 | 3 |
| Hyperphagia | 3 | 3 |
| Feeding and Eating Disorders 2 sub-diseases | 1 | 2 |
| Abdominal Pain 1 sub-disease | 1 | 1 |
| Dyspepsia | 1 | 1 |
| Encopresis | 1 | 1 |
2 more with no active trials: Flatulence, Heartburn
About
- Summary
- 25 drugs are in active Digestive Signs and Symptoms trials: 3 approved, 10 in Phase 3, 12 earlier. The next Phase 3 result expected is Tradipitant’s, 1 Dec 2026. Updated 20 Nov 2026.
- Registry term
- Signs and Symptoms, Digestive
- Counts
- Active trials the registry tags with the term or a term under it, at any stage. A search also reads trial titles and drug names, so its counts differ.
- Sources
- ClinicalTrials.gov updated 20 Nov 2026